ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TLOG TetraLogic Pharmaceuticals Corporation (CE)

0.000001
0.00 (0.00%)
29 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
TetraLogic Pharmaceuticals Corporation (CE) USOTC:TLOG OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.000001 0.00 01:00:00

TetraLogic to Present at the Cowen and Company 34th Annual Health Care Conference

26/02/2014 12:30pm

GlobeNewswire Inc.


TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more TetraLogic Pharmaceuticals (CE) Charts.

TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the Cowen and Company 34th Annual Health Care Conference on Wednesday, March 5, 2014 at 8:40 a.m. Eastern Time in Boston, MA. Mr. Buchi will provide an overview of the Company and its corporate activities.

The presentation will be webcast live and may be accessed by visiting TetraLogic's website at http://ir.tetralogicpharma.com. A replay of the webcast will be available for 10 business days.

About TetraLogic

Tetralogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases, or SMAC-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body's immune system to self-destruct.  Birinapant, our clinical-stage product candidate, is currently being tested in Phase 1 and Phase 2 oncology clinical trials for hematological malignancies and multiple solid tumors.

CONTACT: Company Contact:
         Pete A. Meyers
         Chief Financial Officer and Treasurer
         TetraLogic Pharmaceuticals Corporation
         (610) 889-9900, x103
         pete.meyers@tlog.com
         
         Investor Relations Contact:
         Ami Bavishi
         Burns McClellan, Inc.
         (212) 213-0006
         abavishi@burnsmc.com

1 Year TetraLogic Pharmaceuticals (CE) Chart

1 Year TetraLogic Pharmaceuticals (CE) Chart

1 Month TetraLogic Pharmaceuticals (CE) Chart

1 Month TetraLogic Pharmaceuticals (CE) Chart